TRT for Veterans: A Complete Clinical Guide to Testosterone Therapy After Military Service

Why Veterans Are at Higher Risk for Low Testosterone

Veterans carry a disproportionate burden of the exact medical conditions that disrupt the hypothalamic-pituitary-gonadal (HPG) axis. A 2021 analysis published in JAMA Network Open (N=4,915 Operation Enduring Freedom/Operation Iraqi Freedom veterans) found that 19.4% of screened veterans met laboratory criteria for hypogonadism, compared with a community prevalence of roughly 10% in men aged 40 to 69 years reported in the Massachusetts Male Aging Study [1][2]. Three mechanisms account for most of this gap.

Traumatic brain injury. An estimated 22% of all combat casualties in Iraq and Afghanistan involved TBI [3]. The pituitary gland sits directly below the hypothalamus and is highly vulnerable to blast overpressure. A systematic review in The Journal of Clinical Endocrinology and Metabolism (2013) found pituitary dysfunction in 15-40% of patients one year after moderate-to-severe TBI, with growth hormone and gonadotropin deficiencies being most common [4]. Veterans with a documented TBI history should receive pituitary hormone screening regardless of age.

PTSD and chronic stress. Chronically elevated cortisol suppresses gonadotropin-releasing hormone (GnRH) pulsatility. A study in Psychoneuroendocrinology (2014, N=300 male veterans) found total testosterone averaged 287 ng/dL in veterans with active PTSD versus 412 ng/dL in non-PTSD controls (P<0.001) [5]. Low testosterone and PTSD share symptom overlap, including poor sleep, irritability, and blunted motivation, making careful differential diagnosis necessary.

Opioid-induced hypogonadism. Chronic opioid use suppresses LH and FSH secretion. Between 40% and 60% of men on long-term opioid therapy develop secondary hypogonadism [6]. Veterans with musculoskeletal injuries treated with chronic opioids are therefore a high-risk subgroup requiring routine testosterone screening.

How TRT Is Accessed Through the VA

The Department of Veterans Affairs covers testosterone replacement therapy when a veteran meets two criteria: a total testosterone below 300 ng/dL on two separate morning blood draws, and at least one clinical symptom of hypogonadism such as decreased libido, fatigue, or loss of muscle mass [7]. The VA formulary primarily stocks testosterone cypionate for injection and testosterone gel (AndroGel 1.62%). Testosterone pellets (Testopel) and testosterone undecanoate (Aveed) are available at some VA facilities but require non-formulary approval.

Veterans who prefer telehealth access outside the VA can use private providers, though out-of-pocket costs for testosterone cypionate typically run $30 to $80 per month including syringes and ancillary medications. For veterans with both VA coverage and private insurance, the VA pharmacy is usually the more cost-effective channel.

The HealthRX Veterans TRT Access Decision Framework

1. Request baseline labs through VA primary care or a telehealth provider: total testosterone (7-10 AM draw), free testosterone, LH, FSH, prolactin, complete blood count, comprehensive metabolic panel, PSA, and estradiol.
2. If total testosterone is below 300 ng/dL on two draws AND symptoms are present, initiate TRT discussion.
3. If LH and FSH are low alongside low testosterone (secondary hypogonadism pattern), order an MRI of the pituitary to rule out structural pathology, especially in any veteran with a TBI history.
4. Choose delivery method based on adherence preference, skin-contact risk (gels are contraindicated in households with children or female partners who may be exposed), and hematocrit trend.
5. Recheck labs at 6-8 weeks after starting, then at 3 months, then every 6 months once stable.

TRT Over 50: What Changes After Middle Age

Men over 50 represent the largest group seeking TRT through the VA. Testosterone declines at approximately 1-2% per year after age 30 [8], so a 55-year-old veteran who started at 700 ng/dL may measure in the low 300s or below without any additional pathology driving the decline.

The TTrials (Testosterone Trials), a coordinated set of seven placebo-controlled trials funded by the NIH (N=790 men aged 65 or older with total testosterone below 275 ng/dL), provide the most rigorous evidence for men in this age bracket [9]. The Sexual Function Trial showed significant improvement in sexual desire, activity, and erectile function with testosterone gel versus placebo at 12 months. The Physical Function Trial showed modest but statistically significant improvements in walking distance. The Bone Trial, published in JAMA Internal Medicine, demonstrated that one year of testosterone treatment increased volumetric bone mineral density at the lumbar spine by 7.5% and trabecular bone score by 11.2% versus placebo (P<0.001) [10].

Cardiovascular monitoring becomes more consequential after 50. The Endocrine Society's 2018 Clinical Practice Guideline states: "We suggest that clinicians assess cardiovascular risk factors and discuss potential CV risks with patients before initiating testosterone therapy" [11]. Specifically, hematocrit should be checked at baseline and at 3-6 month intervals. If hematocrit climbs above 54%, dose reduction or therapeutic phlebotomy is indicated before continuing.

TRT Over 65: Special Considerations for Older Veterans

Veterans over 65 face a narrower benefit-risk window than younger men, and the evidence base, while supportive, carries more nuance. The TTrials found no statistically significant increase in cardiovascular events in the active treatment group versus placebo over 12 months, but the study was not powered for long-term cardiovascular endpoints [9]. The FDA-mandated label update in 2015 added a cardiovascular risk warning to all testosterone products based on observational data, though the direction of causality remains debated in the literature [12].

Prostate safety is the other central concern. The current Endocrine Society guideline does not list prostate cancer history as an absolute contraindication in men who have been treated with curative intent and have undetectable PSA for at least two years, but it recommends a urology consultation before initiation [11]. Veterans with elevated PSA at baseline require full urological clearance before starting TRT.

Bone health is a genuine win at this age. Osteoporosis affects roughly 1 in 4 men over 70, and hypogonadism is a recognized secondary cause [13]. A meta-analysis in Osteoporosis International (2016, 35 trials) found testosterone therapy increased lumbar spine BMD by a mean of 5.8% and femoral neck BMD by 3.1% over 12-36 months [14]. Veterans with documented hypogonadism and osteopenia should have their TRT decision framed partly around fracture risk reduction.

TRT for Younger Veterans (Under 40)

Secondary hypogonadism from TBI, opioids, or PTSD can affect veterans in their 20s and 30s. This group requires a different clinical conversation. Younger men have the most to lose from long-term HPG axis suppression through exogenous testosterone, because TRT will reduce intratesticular testosterone and suppress spermatogenesis within 6 to 12 weeks of starting [15].

For any veteran under 40 who may want biological children, the preferred first approach is often clomiphene citrate 25-50 mg every other day or anastrozole (for men with elevated estradiol suppressing LH), which can raise endogenous testosterone without shutting down sperm production. If a veteran has completed his family or does not want future children, testosterone cypionate or enanthate at 100-200 mg per week remains appropriate.

A 2023 retrospective study in Fertility and Sterility (N=412 men treated with clomiphene for secondary hypogonadism, mean age 32) showed mean total testosterone increase from 227 ng/dL to 489 ng/dL at 12 months, with 78% of men maintaining normal sperm parameters throughout [16]. For younger veterans, this represents a reasonable first-line option before committing to exogenous testosterone.

If exogenous TRT is chosen, co-administration of human chorionic gonadotropin (hCG) at 500-1 to 000 IU subcutaneously three times per week can preserve intratesticular volume and sperm production, though insurance coverage for hCG co-therapy varies widely within the VA system.

TRT for Veterans Who Train: Distinguishing Therapeutic Use from Performance Enhancement

Some veterans use structured resistance training as part of PTSD management or physical rehabilitation, and they want to understand how TRT interacts with training outcomes. This is a legitimate clinical question, distinct from the bodybuilder context of supraphysiologic dosing.

Therapeutic TRT targets serum testosterone in the 400-700 ng/dL mid-cycle range. Supraphysiologic dosing used in bodybuilding contexts targets 1 to 000 ng/dL or higher and involves doses of 500-1 to 000 mg per week, often stacked with other anabolic agents. These are not the same intervention.

The TRAVERSE trial (N=5,246, mean age 57.6 years, published in NEJM 2023) evaluated testosterone replacement at therapeutic doses in men with hypogonadism and established cardiovascular disease or high cardiovascular risk [17]. At a mean follow-up of 33 months, major adverse cardiovascular events occurred in 7.0% of the testosterone group versus 7.3% of the placebo group, a non-inferior result (P<0.001 for non-inferiority). This is the largest randomized trial to date and provides meaningful reassurance for veterans who train and want TRT at therapeutic doses.

Veterans who are performing high-volume resistance training will see faster lean mass accrual on TRT than sedentary men, not because TRT has a drug interaction with exercise, but because testosterone and mechanical loading share downstream anabolic pathways through mTOR and androgen receptor upregulation. This is a feature of restoring normal physiology, not a pharmacological enhancement.

The HealthRX medical team recommends that veterans who combine TRT with regular resistance training get a hematocrit check every 3 months in the first year, since training-driven increases in red blood cell production stack with testosterone-driven erythropoiesis and can push hematocrit toward the 54% threshold faster than in sedentary men.

Monitoring Protocol for Veterans on TRT

Consistent monitoring separates safe long-term TRT from the ad hoc self-administration patterns that cause harm. The Endocrine Society's 2018 guideline specifies the following monitoring schedule [11]:

3-6 months after initiation: Total testosterone (draw at trough for injections, 2-4 hours post-application for gels), hematocrit, PSA. Assess symptom response formally using the Aging Males' Symptoms (AMS) scale or the IIEF-5 for sexual function.

12 months after initiation: Repeat all above plus bone mineral density (DXA scan) in men over 65 or in any veteran with a prior DXA showing osteopenia. Assess lipid panel, since testosterone modestly lowers HDL at higher doses.

Ongoing (every 6-12 months): Total testosterone, hematocrit, PSA. Annual DXA in men with bone disease.

Dr. Bradley Anawalt, a professor of medicine at the University of Washington and co-author of the 2018 Endocrine Society TRT guideline, has stated: "The goal of testosterone therapy is not to achieve the highest testosterone level possible but to achieve the level that relieves symptoms and minimizes risk, typically in the 400 to 700 ng/dL range for most men." [11]

Veterans with a history of polycythemia, untreated sleep apnea, or active prostate pathology require additional clearance before TRT is appropriate. Sleep apnea in particular is common among veterans with PTSD and TBI, and TRT can worsen nocturnal hypoxia by increasing upper airway muscle tone abnormally. A polysomnography or at-home sleep study should precede TRT initiation in any veteran with snoring, witnessed apneas, or Epworth Sleepiness Scale score above 10.

Toxic Exposures and Hormonal Disruption: Agent Orange and Burn Pits

Vietnam-era veterans exposed to Agent Orange and post-9/11 veterans exposed to burn-pit smoke represent two cohorts with incompletely characterized endocrine effects. Dioxin, the primary toxic component of Agent Orange, is a potent endocrine disruptor. A longitudinal study in Environmental Health Perspectives (2010, N=1,025 Vietnam veterans) found serum testosterone was 14% lower in veterans with the highest dioxin quartile versus the lowest, after adjusting for age, BMI, and smoking [18].

Burn-pit exposures, now recognized under the PACT Act (2022), include particulate matter, heavy metals, and volatile organic compounds with known or suspected antiandrogenic activity. The VA's Airborne Hazards and Open Burn Pit Registry has enrolled over 300,000 veterans, but comprehensive hormonal profiling of this cohort remains an active research gap. Veterans who registered in the burn-pit registry and report fatigue, decreased libido, or mood changes should receive explicit testosterone screening as part of their post-deployment health evaluation.

Practical Starting Protocol: What to Expect in the First 6 Months

Veterans starting TRT for the first time should understand the staged onset of benefits. Based on the synthesis of published pharmacokinetic data and clinical trials, the general timeline runs as follows.

Weeks 1 to 3: serum testosterone reaches target range. Some men report improved sleep and reduced irritability within this window, but placebo effects are substantial and not every man notices changes this early.

Weeks 3 to 6: libido and morning erections typically improve. Energy begins to stabilize. This is the window where the AMS scale score typically shows the first measurable drop.

Months 2 to 4: lean mass accrual begins if resistance training is concurrent. Body fat begins to shift, particularly visceral fat. A randomized trial in NEJM (Bhasin et al., 2001, N=61 healthy men) demonstrated that testosterone enanthate 600 mg per week produced fat-free mass gains of 3.2 kg versus 1.9 kg in placebo plus exercise at 10 weeks [19]. At therapeutic doses, gains are more modest but clinically real.

Months 4 to 6: mood stabilization is more durable. Men with PTSD-related anhedonia may notice the most pronounced shift in this window, as testosterone has documented effects on dopaminergic tone and amygdala reactivity.

The first 6-month lab check is the most important one. If total testosterone is below 350 ng/dL at trough and symptoms persist, dose adjustment is warranted. If hematocrit is above 50% but below 54%, frequency reduction (e.g., shifting from weekly to biweekly injections) is usually sufficient.